en / es /

OWL Metabolomics contributes to MASEF Score for Identifying At-Risk MASH Patients

Scroll down
Published on 02/08/2023
By OWL Metabolomics
Share: Linkedin Facebook Twitter

Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF), Published in Hepatology, a Breakthrough in MASH Diagnosis

(Bilbao, August 2, 2023) The prestigious journal <i>Hepatology</i> has just published a cutting-edge study in hepatology. The research, conducted by Dr. Mazen Noureddin, Dr. Emily Truong and Dr. Arun J. Sanyal, with Dr. Rebeca Mayo, Ibon Martínez and Itziar Mincholé from OWL Metabolomics, in collaboration with scientists from institutions and hospitals in Europe and America, has found a metabolic pattern that can identify at-risk MASH patients (MASH with NAS≥4 + F≥2). You can access the study via this link (https://pubmed.ncbi.nlm.nih.gov/37505221/)

MASEF, the New Diagnostic Tool for Evaluating At-Risk MASH Patients

The research focused on the development and validation of the Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF), a metabolomic diagnostic tool for the evaluation of at-risk MASH patients. The MASEF score demonstrated good diagnostic performance, with an area under the curve of 0.76 (95% CI: 0.72-0.79) in the derivation cohort and 0.79 (95% CI: 0.75-0.83) in the validation cohort.

Advantages of the MASEF Score

The study also highlights the advantages of using the MASEF score as a substitute for LSM by VCTE in the FIB-4 + LSM by VCTE algorithm currently recommended by the American Gastroenterology Association (AGA). The MASEF score exhibits similar performance, high accuracy, and greater accessibility as it is a blood-based test. MASEF score was also compared to FAST score, showing similar performance in the validation cohort 0.74 (95% CI 0.68-0.79; p=0.064).

Dr. Mazen Noureddin points out that “the MASEF score could be a practical tool to identify patients at high risk of severe liver disease progression to be targeted for novel pharmacotherapies and clinical trials.”

Significant Contributions to the Field of Hepatology Research

The authors of the study, which includes Jesus M. Bañales, Marco Arrese, Kenneth Cusi, María Teresa Arias-Loste, Radan Brüha, Manuel Romero-Gómez, Paula Iruzubieta, Rocio Aller, Javier Ampuero, José Luis Calleja, Luis Ibañez-Samaniego, Patricia Aspichueta, Antonio Marín-Duce, Tatyana Kushner, Pablo Ortiz, Stephen A. Harrison, Quentin M. Anstee, Javier Crespo and José M. Mato, have made significant contributions to the advancement of knowledge in this critical field of research.

About OWL Metabolomics

OWL Metabolomics is a global provider of metabolomics services to the pharmaceutical industry, primarily focused on supporting clinical trials in liver diseases and other prevalent human diseases. It also focuses on research in indications where metabolomics plays a key role, including drug therapy monitoring and biomarker discovery.

Since its inception in 2002, the Basque company has collaborated with numerous MASH pharmaceutical and biotechnology companies and research organizations around the world in the hepatology field, thanks to the creation of its exclusive metabolomic analysis platform. Additionally, OWL Metabolomics develops and markets non-invasive diagnostic tools based on metabolomics.

We use our own and third-party cookies to be able to correctly offer you all the functionalities of the website, for analytical purposes and to show you personalized advertising according to a profile prepared from your browsing habits. You can accept all cookies by clicking "Accept cookies", obtain more information in our" Cookie policy or configure them or reject their use by clicking on Configuration.".
Accept Cookies Configure
Basic cookie information
This website uses cookies and/or similar technologies that store and retrieve information when you browse. In general, these technologies can serve very different purposes, such as, for example, recognizing you as a user, obtaining information about your browsing habits or customizing the way in which the content is displayed. The specific uses we make of these technologies are described below. By default, all cookies are disabled, except for the technical ones, which are necessary for the website to work. If you wish to expand the information or exercise your data protection rights, you can consult our Cookies Policy.".
Accept cookies Manage preferences
Technical and/or necessary cookies Always active
Technical cookies are those that facilitate user navigation and the use of the different options or services offered by the web such as identifying the session, allowing access to certain areas, facilitating orders, purchases, filling in forms, registration, security, facilitating functionalities. (videos, social networks…).
Analysis cookies
Analysis cookies are those used to carry out anonymous analysis of the behavior of web users and that allow user activity to be measured and navigation profiles to be created with the objective of improving websites.
Confirm preferences
Linkedin Twitter
By Rubió
Carrer Indústria 29, Polígon Industrial Comte de Sert 08755
Castellbisbal, Barcelona (España), +34 937 722 509labrubio@labrubio.com